United Therapeutics Co. (NASDAQ:UTHR) Director Sells $797,000.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Down 1.0 %

Shares of United Therapeutics stock traded down $3.13 during trading hours on Tuesday, reaching $316.73. 345,532 shares of the company’s stock were exchanged, compared to its average volume of 446,533. The firm has a market capitalization of $14.22 billion, a price-to-earnings ratio of 13.91, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The company has a fifty day moving average of $344.24 and a 200-day moving average of $356.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wealthfront Advisers LLC increased its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of United Therapeutics by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC increased its holdings in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after buying an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.